Review top news and interview highlights from the week ending July 22, 2022.
Welcome to CGTLive’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.
PLX-PAD is also being studied for the treatment of steroid-refractory chronic graft versus host disease.
The principal investigator of the HOPE-2 trial discussed results of the trial in the non-ambulatory population of patients with Duchenne muscular dystrophy.
WU-CART-007 has been granted fast track, rare pediatric disease, and orphan drug designations.
The professor of neurosurgery at Rush University Medical School discussed data seen in the phase 1/2 clinical trial of LCTOPC1.
Ofra-vec continues to be evaluated in phase 2 trials for glioblastoma and colorectal cancer.